文献速递前列腺癌

局限性前列腺癌主动监测:全国性观察研究

Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study.
PubMed 文献 · J Urol · 2019-01-01

该研究纳入丹麦2002至2012年936例接受主动监测的局限性前列腺癌男性,中位随访7.5年。10年病因特异性生存率为99.6%,支持对局限性前列腺癌(包括有利中危)采用主动监测。

要点

  • 10年病因特异性生存率达99.6%,与前瞻性主动监测队列相似。
  • 中危组 curative treatment-free 生存率高于低危组(69% vs 56%,p=0.008)。
  • 中危组激素治疗-free生存率低于低危组(88% vs 95%,p=0.005)。

核心结论

  • 全国性队列中10年病因特异性生存率与前瞻性主动监测队列相似。
  • 研究支持对局限性前列腺癌男性(包括有利中危特征者)使用主动监测。

研究设计与样本

  • 全国性观察研究,纳入2002至2012年丹麦936例接受主动监测的局限性前列腺癌男性。
  • 中位随访7.5年(IQR 6.1-9.1)。

主要发现

  • 风险分组:极低危223例,低危436例,中危259例(87%为有利中危),高危18例。
  • 10年 curative treatment-free 生存率为62.8%(95%CI 59.1-66.3)。
  • 10年激素治疗-free生存率为92.2%(95%CI 89.2-94.4)。
  • 10年去势抵抗性前列腺癌-free生存率为97.2%(95%CI 95.3-98.4)。
  • 10年病因特异性生存率为99.6%(95%CI 98.6-99.9)。

关键数值与推荐

  • 与低危相比,中危组 curative treatment-free 生存率更高(69% vs 56%,p=0.008)。
  • 与低危相比,中危组激素治疗-free生存率更低(88% vs 95%,p=0.005)。
  • 与低危相比,中危组去势抵抗性前列腺癌-free生存率相似(95% vs 99%,p=0.17)。

临床怎么用

  • 局限性前列腺癌男性可考虑主动监测,包括有利中危特征者。
  • 主动监测期间需关注中危患者激素治疗需求可能增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to investigate nationwide survival outcomes in men with localized prostate cancer managed on active surveillance. MATERIALS AND METHODS: A total of 936 men with localized prostate cancer were initiated on active surveillance in Denmark in 2002 to 2012. Kaplan-Meier estimated curative treatment-free, hormonal therapy-free, castration resistant prostate cancer-free and cause specific survival was calculated. RESULTS: Prostate cancer was classified as very low risk in 223 men, low risk in 436, intermediate risk in 259 (87% were at favorable intermediate risk) and high risk in 18. Median followup was 7.5 years (IQR 6.1-9.1). Kaplan-Meier estimated 10-year curative treatment-free survival was 62.8% (95% CI 59.1-66.3), 10-year hormonal therapy-free survival was 92.2% (95% CI 89.2-94.4), 10-year castration resistant prostate cancer-free survival was 97.2% (95% CI 95.3-98.4) and 10-year cause specific survival was 99.6% (95% CI 98.6-99.9). Compared to men with low risk prostate cancer, those with intermediate risk prostate cancer had higher curative treatment-free survival (69% vs 56%, p = 0.008), lower hormonal therapy-free survival (88% vs 95%, p = 0.005) and similar castration resistant prostate cancer-free survival (95% vs 99%, p = 0.17). CONCLUSIONS: In this nationwide cohort 10-year cause specific survival was similar to that in prospective active surveillance cohorts. Our study supports the use of active surveillance in men with localized prostate cancer, including men with favorable intermediate risk characteristics.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Thomsen FB, Jakobsen H, Langkilde NC, et al. Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study. J Urol. 2019. PMID: 30240689. doi:10.1016/j.juro.2018.09.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。